Laboratorios Rovi (ROVI): analysis in plain words
Is Laboratorios Rovi cheap or expensive? How it makes money, whether it grows and its risks, explained in plain words and with its official accounts.
Laboratorios Rovi (ROVI) is listed on the Madrid Stock Exchange and we classify it in healthcare and pharma. Below are its key dated figures, how it makes money, how it compares with its sector, what works for and against Laboratorios Rovi according to those figures, and the questions people ask most about the stock. No buy or sell tips.
Laboratorios Rovi (ROVI) key figures as of November 4, 2026
| Figure | Value | What it measures |
|---|---|---|
| Share price | €63.75 | Last price on November 4, 2026 |
| P/E ratio (TTM) | 17.6x | Price over earnings per share |
| Revenue growth | +20.0% | Latest quarter vs the same quarter a year earlier |
| Net margin (TTM) | 24.0% | Profit for every 100 of sales |
| Net debt / EBITDA | Net cash (more cash than debt) | Years of operating profit to repay debt |
| Dividend yield | 1.52% | Annual dividend over price |
| Market cap | €3.3 billion | What the stock market values it at |
The Laboratorios Rovi figures come from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026. Any ROVI figure that is not available shows as N/A: we do not estimate it.
How Laboratorios Rovi makes money
Rovi has two businesses. Specialty pharmaceuticals, its biggest, sells heparins such as biosimilar enoxaparin and bemiparin, plus drugs like the schizophrenia treatment Okedi. Its contract manufacturing arm produces injectable drugs and vaccines for other drugmakers, including Moderna. Spain is its largest market.
Over the last 12 months, Laboratorios Rovi brought in revenue of €773 million. For every 100 it sells, Laboratorios Rovi keeps 64.7 after the direct cost of what it sells (gross margin) and 9.4 after all operating costs (operating margin).
Laboratorios Rovi against its sector
To know whether a Laboratorios Rovi figure is high or low you have to put it next to similar companies. This table compares Laboratorios Rovi with the median of the 30 healthcare and pharma companies Fintols covers, with data as of November 4, 2026.
| Figure | Laboratorios Rovi | healthcare and pharma median |
|---|---|---|
| P/E | 17.6x | 31.3x (30) |
| Revenue growth | +20.0% | +8.3% (33) |
| Net margin | 24.0% | 14.9% (33) |
| Dividend yield | 1.52% | 1.52% (33) |
| Net debt / EBITDA | -0.1x | 1.6x (31) |
In short, against the typical healthcare and pharma company, Laboratorios Rovi trades on a lower P/E, grows faster and earns a wider margin. By size, Laboratorios Rovi ranks number 5 of 5 healthcare and pharma companies quoted in EUR on Fintols.
The bull case for Laboratorios Rovi
What works in favour of Laboratorios Rovi, according to its figures as of November 4, 2026:
- Laboratorios Rovi grew sales +20.0% in its latest quarter against the same quarter a year earlier, while the median healthcare and pharma company Fintols tracks grew +8.3%.
- Laboratorios Rovi keeps 24.0 of every 100 it sells as net profit, against 14.9 for the median healthcare and pharma company: a margin like that leaves money to invest, buy back shares or pay dividends.
- Laboratorios Rovi earns 28.6% a year on its shareholders' money (return on equity).
The main risk for Laboratorios Rovi
The Laboratorios Rovi figures as of November 4, 2026 show no clear red flag (no heavy debt, no losses, no falling sales). Its main risk is the one built into its business: a key drug losing patent protection or a clinical trial failing, plus government pressure on prices.
Frequently asked questions about Laboratorios Rovi
Is it a good time to buy Laboratorios Rovi stock?
Fintols does not tell you whether to buy or sell Laboratorios Rovi, and nobody knows what the price will do tomorrow. What we can show you is where it stands today. As of November 4, 2026, Laboratorios Rovi stock trades at €63.75, 26% below its 52-week high (€86.70) and 20% above its low (€53.10). Its P/E is 17.6x against a healthcare and pharma median of 31.3x, and 19.4x on the earnings analysts expect over the next 12 months. With Laboratorios Rovi, as with any stock, timing matters less than understanding the business, investing for the long run and not betting everything on a single company.
Does Laboratorios Rovi pay a dividend?
Yes. As of November 4, 2026, Laboratorios Rovi pays €0.96 per share a year, which at today's price is a yield of 1.52%. It uses 26% of its profit to pay it, which leaves room to keep paying it if profit dips. The healthcare and pharma median on Fintols is 1.52%.
Is Laboratorios Rovi stock expensive?
It depends on what you compare it with. On P/E, Laboratorios Rovi trades at 17.6x its last 12 months of earnings: cheaper than the healthcare and pharma median (31.3x). Including its debt, Laboratorios Rovi is valued at 18.3x its EBITDA (EV/EBITDA). A high P/E alone does not make Laboratorios Rovi expensive: it can be justified if earnings grow fast, and a low one can reflect a business in trouble.
Who are Laboratorios Rovi's competitors?
On Fintols we compare Laboratorios Rovi with Grifols, Bayer and argenx, which are also in healthcare and pharma. As of November 4, 2026, Grifols is worth €7.6 billion and trades on a P/E of 15.8; Bayer is worth €53.3 billion; argenx is worth €51.3 billion and trades on a P/E of 32.8. Each has a side-by-side comparison with Laboratorios Rovi below.
Laboratorios Rovi competitors
- Grifols (GRF) analysis · Laboratorios Rovi vs Grifols comparison
- Bayer (BAYN.DE) analysis · Laboratorios Rovi vs Bayer comparison
- argenx (ARGX.BR) analysis · Laboratorios Rovi vs argenx comparison
To understand Laboratorios Rovi better
- DCF and WACC Explained: A Practical Valuation Guide
- P/E Ratio and EPS Explained: How to Read Them Without Traps
More companies like Laboratorios Rovi: healthcare and pharma stocks and IBEX 35 companies. Open the full ROVI analysis with its valuation and scenarios. Educational content about Laboratorios Rovi, not investment advice.